AR045423A1 - Combinaciones de analiticos y antidepresivos - Google Patents
Combinaciones de analiticos y antidepresivosInfo
- Publication number
- AR045423A1 AR045423A1 ARP040101623A ARP040101623A AR045423A1 AR 045423 A1 AR045423 A1 AR 045423A1 AR P040101623 A ARP040101623 A AR P040101623A AR P040101623 A ARP040101623 A AR P040101623A AR 045423 A1 AR045423 A1 AR 045423A1
- Authority
- AR
- Argentina
- Prior art keywords
- fluoxetine
- antidepressants
- paroxetine
- antidepressant
- hydrochloride
- Prior art date
Links
- 239000000935 antidepressant agent Substances 0.000 title abstract 5
- 229940005513 antidepressants Drugs 0.000 title abstract 5
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 230000001430 anti-depressive effect Effects 0.000 abstract 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 abstract 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 abstract 2
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 abstract 2
- 229960002464 fluoxetine Drugs 0.000 abstract 2
- 229960001165 modafinil Drugs 0.000 abstract 2
- 229960002296 paroxetine Drugs 0.000 abstract 2
- FGBFEFJZYZDLSZ-UHFFFAOYSA-N 5,7-dimethoxy-2,3-dimethyl-2,3-dihydroinden-1-one Chemical compound COC1=CC(OC)=CC2=C1C(=O)C(C)C2C FGBFEFJZYZDLSZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 abstract 1
- 229960001564 clomipramine hydrochloride Drugs 0.000 abstract 1
- 238000002651 drug therapy Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960000389 fluoxetine hydrochloride Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960005183 paroxetine hydrochloride Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46994303P | 2003-05-13 | 2003-05-13 | |
| US10/844,187 US20040229942A1 (en) | 2003-05-13 | 2004-05-12 | Analeptic and antidepressant combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045423A1 true AR045423A1 (es) | 2005-10-26 |
Family
ID=33423928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101623A AR045423A1 (es) | 2003-05-13 | 2004-05-11 | Combinaciones de analiticos y antidepresivos |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20040229942A1 (enExample) |
| EP (1) | EP1628652B1 (enExample) |
| JP (1) | JP5553955B2 (enExample) |
| KR (1) | KR20060019537A (enExample) |
| AR (1) | AR045423A1 (enExample) |
| AU (1) | AU2004238379B2 (enExample) |
| BR (1) | BRPI0411174A (enExample) |
| CA (1) | CA2525524C (enExample) |
| CY (1) | CY1113154T1 (enExample) |
| DK (1) | DK1628652T3 (enExample) |
| EA (1) | EA012173B1 (enExample) |
| ES (1) | ES2390225T3 (enExample) |
| HR (1) | HRP20120713T1 (enExample) |
| IS (1) | IS8097A (enExample) |
| MX (1) | MXPA05012144A (enExample) |
| MY (1) | MY140179A (enExample) |
| NO (1) | NO334448B1 (enExample) |
| NZ (1) | NZ544135A (enExample) |
| PL (1) | PL1628652T3 (enExample) |
| PT (1) | PT1628652E (enExample) |
| SI (1) | SI1628652T1 (enExample) |
| TW (1) | TWI409061B (enExample) |
| UA (1) | UA89753C2 (enExample) |
| WO (1) | WO2004100937A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03000747A (es) * | 2000-07-27 | 2003-06-04 | Teva Pharma | Modafinilo cristalino y puro y proceso para prepararlo. |
| US6992219B2 (en) * | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
| US20040229941A1 (en) * | 2003-05-13 | 2004-11-18 | Cephalon, Inc. | Analeptic and antidepressant combinations |
| US20040242698A1 (en) * | 2003-05-13 | 2004-12-02 | Cephalon Inc. | Analeptic and antidepressant combinations |
| AR045314A1 (es) * | 2003-05-13 | 2005-10-26 | Cephalon Inc | Composiciones farmaceuticas de analepticos y antidepresivos |
| US20040229943A1 (en) * | 2003-05-16 | 2004-11-18 | Cephalon Inc | Analeptic and drug combinations |
| CN1819821B (zh) | 2003-08-08 | 2010-10-13 | 拜奥维尔实验室国际股份有限公司 | 盐酸安非他酮的改良释放片剂 |
| US7368591B2 (en) | 2003-09-19 | 2008-05-06 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
| EP1909573A4 (en) * | 2005-07-21 | 2010-09-22 | Neurohealing Pharmaceuticals I | SHORT-TERM EFFECTIVE MODAFINIL COMPOSITIONS WITH A RAPID INITIAL EFFECT, AND METHOD FOR THEIR USE |
| DK2056811T3 (en) * | 2006-08-14 | 2018-05-22 | Neurohealing Pharmaceuticals Inc | Modafinil-based treatment for premature ejaculation |
| JP6614014B2 (ja) * | 2016-04-26 | 2019-12-04 | 信越化学工業株式会社 | 含窒素オルガノキシシラン化合物およびその製造方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2593809B1 (fr) * | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
| FR2663225B1 (fr) * | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
| FR2684875B1 (fr) * | 1991-12-13 | 1995-05-24 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique. |
| FR2697162B1 (fr) * | 1992-10-23 | 1995-01-13 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux. |
| FR2706767B1 (enExample) * | 1993-06-22 | 1995-09-08 | Lafon Labor | |
| US5933841A (en) * | 1996-05-17 | 1999-08-03 | Ameritech Corporation | Structured document browser |
| US5890172A (en) * | 1996-10-08 | 1999-03-30 | Tenretni Dynamics, Inc. | Method and apparatus for retrieving data from a network using location identifiers |
| FR2771004B1 (fr) * | 1997-11-19 | 2000-02-18 | Inst Curie | Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse |
| US6359635B1 (en) * | 1999-02-03 | 2002-03-19 | Cary D. Perttunen | Methods, articles and apparatus for visibly representing information and for providing an input interface |
| US6346548B1 (en) * | 1999-08-16 | 2002-02-12 | Cephalon, Inc. | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| US6455588B1 (en) * | 1999-08-20 | 2002-09-24 | Cephalon, Inc. | Compositions including modafinil for treatment of eating disorders and for appetite stimulation |
| US6503950B1 (en) * | 1999-08-23 | 2003-01-07 | David M. Ockert | Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms |
| US20010034373A1 (en) * | 2000-02-09 | 2001-10-25 | Matthew Miller | Low dose modafinil for enhancement of cognitive function |
| US6417184B1 (en) * | 2000-09-19 | 2002-07-09 | David M. Ockert | Triple drug therapy for the treatment and prevention of acute or chronic pain |
| US20030036555A1 (en) * | 2001-08-03 | 2003-02-20 | Boehringer Ingelheim Pharma Kg | Pramipexole for the treatment of ADHD |
| AR045314A1 (es) * | 2003-05-13 | 2005-10-26 | Cephalon Inc | Composiciones farmaceuticas de analepticos y antidepresivos |
| US20040242698A1 (en) * | 2003-05-13 | 2004-12-02 | Cephalon Inc. | Analeptic and antidepressant combinations |
| US20040229941A1 (en) * | 2003-05-13 | 2004-11-18 | Cephalon, Inc. | Analeptic and antidepressant combinations |
| US20040229943A1 (en) * | 2003-05-16 | 2004-11-18 | Cephalon Inc | Analeptic and drug combinations |
-
2004
- 2004-05-11 AR ARP040101623A patent/AR045423A1/es unknown
- 2004-05-12 US US10/844,187 patent/US20040229942A1/en not_active Abandoned
- 2004-05-13 CA CA2525524A patent/CA2525524C/en not_active Expired - Fee Related
- 2004-05-13 EP EP04761006A patent/EP1628652B1/en not_active Expired - Lifetime
- 2004-05-13 WO PCT/US2004/015194 patent/WO2004100937A1/en not_active Ceased
- 2004-05-13 PT PT04761006T patent/PT1628652E/pt unknown
- 2004-05-13 MX MXPA05012144A patent/MXPA05012144A/es active IP Right Grant
- 2004-05-13 TW TW093113421A patent/TWI409061B/zh not_active IP Right Cessation
- 2004-05-13 JP JP2006533080A patent/JP5553955B2/ja not_active Expired - Lifetime
- 2004-05-13 KR KR1020057021553A patent/KR20060019537A/ko not_active Ceased
- 2004-05-13 UA UAA200511839A patent/UA89753C2/ru unknown
- 2004-05-13 NZ NZ544135A patent/NZ544135A/en not_active IP Right Cessation
- 2004-05-13 EA EA200501802A patent/EA012173B1/ru not_active IP Right Cessation
- 2004-05-13 ES ES04761006T patent/ES2390225T3/es not_active Expired - Lifetime
- 2004-05-13 MY MYPI20041788A patent/MY140179A/en unknown
- 2004-05-13 HR HRP20120713TT patent/HRP20120713T1/hr unknown
- 2004-05-13 PL PL04761006T patent/PL1628652T3/pl unknown
- 2004-05-13 BR BRPI0411174-5A patent/BRPI0411174A/pt not_active IP Right Cessation
- 2004-05-13 SI SI200431933T patent/SI1628652T1/sl unknown
- 2004-05-13 AU AU2004238379A patent/AU2004238379B2/en not_active Ceased
- 2004-05-13 DK DK04761006.8T patent/DK1628652T3/da active
-
2005
- 2005-10-27 IS IS8097A patent/IS8097A/is unknown
- 2005-11-17 NO NO20055450A patent/NO334448B1/no not_active IP Right Cessation
-
2012
- 2012-09-28 CY CY20121100892T patent/CY1113154T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1113154T1 (el) | 2016-04-13 |
| ES2390225T3 (es) | 2012-11-07 |
| SI1628652T1 (sl) | 2012-11-30 |
| WO2004100937B1 (en) | 2006-12-21 |
| EA012173B1 (ru) | 2009-08-28 |
| AU2004238379B2 (en) | 2009-08-20 |
| WO2004100937A1 (en) | 2004-11-25 |
| EP1628652A1 (en) | 2006-03-01 |
| TW200500063A (en) | 2005-01-01 |
| HK1087645A1 (en) | 2006-10-20 |
| PL1628652T3 (pl) | 2012-12-31 |
| CA2525524A1 (en) | 2004-11-25 |
| NO20055450L (no) | 2006-02-01 |
| AU2004238379A1 (en) | 2004-11-25 |
| IS8097A (is) | 2005-10-27 |
| KR20060019537A (ko) | 2006-03-03 |
| DK1628652T3 (da) | 2012-10-08 |
| UA89753C2 (ru) | 2010-03-10 |
| NO20055450D0 (no) | 2005-11-17 |
| JP5553955B2 (ja) | 2014-07-23 |
| MXPA05012144A (es) | 2006-02-08 |
| US20040229942A1 (en) | 2004-11-18 |
| BRPI0411174A (pt) | 2006-07-18 |
| EA200501802A1 (ru) | 2006-06-30 |
| NZ544135A (en) | 2008-09-26 |
| PT1628652E (pt) | 2012-09-28 |
| MY140179A (en) | 2009-11-30 |
| TWI409061B (zh) | 2013-09-21 |
| CA2525524C (en) | 2012-09-25 |
| NO334448B1 (no) | 2014-03-03 |
| EP1628652B1 (en) | 2012-07-11 |
| JP2007505156A (ja) | 2007-03-08 |
| HRP20120713T1 (hr) | 2012-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| BR112022019085A2 (pt) | Uso de agentes para tratamento de condições respiratórias | |
| AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
| CL2023003259A1 (es) | Composiciones y métodos para el tratamiento de la depresión. | |
| ATE399005T1 (de) | Pharmazeutische zusammensetzung aus einem beta-3- adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor und deren verwendung zur behandlung von blasenfunktionsstoerungen | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| KR980000447A (ko) | 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물 | |
| ATE506059T1 (de) | Therapie zur behandlung der überaktiven blase | |
| AR047719A1 (es) | Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion que comprenden un ligando alfa-2-delta y un ssri y/o un snri | |
| AR074313A1 (es) | Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo. uso. kit | |
| DE122009000036I1 (de) | Verwendung von Dapoxetin, A selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Disfunktion | |
| PE20240885A1 (es) | Sales agonistas de sstr4 | |
| CL2011001093A1 (es) | Compuestos derivados de 4-[2-(2-fluorofenoximetil)fenil]piperidina, inhibidores de la recaptacion de serotonina y norepinefrina; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para tratar el dolor neuropatico, fibromialgia, trastorno depresivo y obesidad entre otras. | |
| EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
| CO6280474A2 (es) | Composicion farmaceutica para el tratamiento de la eyaculacion precoz | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| WO2004100939B1 (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
| CO2023006028A2 (es) | Formulación combinada oral que incluye gemigliptina y dapagliflozina y método de preparación para la misma | |
| CA2525524A1 (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
| AR047716A1 (es) | Combinaciones de analepticos y antidepresivos | |
| AR045314A1 (es) | Composiciones farmaceuticas de analepticos y antidepresivos | |
| BRPI0507745A (pt) | compostos de azetidina substituìda como inibidores de ciclooxigenase-1-ciclooxigenase-2, processo para a sua preparação, medicamentos e seus usos | |
| Berrocoso et al. | P. 4.03 Effect of the combinations of weak-opiate analgesics with antidepressants in the tail suspension test | |
| AR127946A1 (es) | ESTIMULADOR TREG SELECTIVO RUR₂₀ₖD-IL-2 Y COMPOSICIONES RELACIONADAS | |
| MX2025013233A (es) | Formas polimorficas y formulaciones de leriglitazona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |